SG48115A1 - Inhibition of retrovirus infection - Google Patents

Inhibition of retrovirus infection

Info

Publication number
SG48115A1
SG48115A1 SG1996007118A SG1996007118A SG48115A1 SG 48115 A1 SG48115 A1 SG 48115A1 SG 1996007118 A SG1996007118 A SG 1996007118A SG 1996007118 A SG1996007118 A SG 1996007118A SG 48115 A1 SG48115 A1 SG 48115A1
Authority
SG
Singapore
Prior art keywords
inhibition
retrovirus infection
slpi
prevention
methods
Prior art date
Application number
SG1996007118A
Other languages
English (en)
Inventor
Robert C Thomson
Sharon M Wahl
Stephen Eisenberg
Amgen Boulder
Original Assignee
Amgen Boulder Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc, Us Health filed Critical Amgen Boulder Inc
Publication of SG48115A1 publication Critical patent/SG48115A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG1996007118A 1992-09-09 1993-09-09 Inhibition of retrovirus infection SG48115A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94336992A 1992-09-09 1992-09-09

Publications (1)

Publication Number Publication Date
SG48115A1 true SG48115A1 (en) 1998-04-17

Family

ID=25479533

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996007118A SG48115A1 (en) 1992-09-09 1993-09-09 Inhibition of retrovirus infection

Country Status (23)

Country Link
EP (1) EP0666755B1 (fr)
JP (2) JP3517238B2 (fr)
KR (1) KR100273620B1 (fr)
AT (1) ATE238062T1 (fr)
AU (1) AU681350B2 (fr)
CA (1) CA2141951C (fr)
CZ (1) CZ286953B6 (fr)
DE (1) DE69332904T2 (fr)
DK (1) DK0666755T3 (fr)
ES (1) ES2197153T3 (fr)
FI (1) FI951078A0 (fr)
HU (1) HU218892B (fr)
NO (1) NO315546B1 (fr)
NZ (1) NZ256246A (fr)
OA (1) OA10133A (fr)
PL (1) PL307864A1 (fr)
PT (1) PT666755E (fr)
RO (1) RO116164B1 (fr)
RU (1) RU2126266C1 (fr)
SG (1) SG48115A1 (fr)
SK (1) SK281127B6 (fr)
UA (1) UA41338C2 (fr)
WO (1) WO1994006454A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507165A (pt) * 1994-03-23 1997-09-09 Tokyo Tanase Company Limited Inibidor da triptase clara agente terapêutico ou profilático para doenças virais processo terapêutico para doenças virais e uso da antileucoprotease
WO1997003694A1 (fr) * 1995-07-24 1997-02-06 Tokyo Tanabe Company Limited Remede contre les affections virales
EP0861085B1 (fr) 1995-11-13 2005-07-20 Vitaleech Bioscience N.V. Isolats antiviraux obtenus a partir de sangsues
AU780121B2 (en) * 1999-05-13 2005-03-03 Japan Science And Technology Agency Inhibitors for viral infection targeting integrase N-terminal region
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
WO2005046732A2 (fr) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methodes et compositions d'inhibition de la replication du vih-1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340877C (fr) * 1987-12-28 2000-01-18 Takashi Sugiyama Polypeptide inhibant l'elastage et procede de production par la technologie de l'adn recombinant
JP2804979B2 (ja) * 1988-11-28 1998-09-30 日本ケミカルリサーチ株式会社 エイズ治療および阻害剤
CA2007083A1 (fr) * 1989-01-09 1990-07-09 Nobuhiko Katunuma Usage pharmaceutique du trypstatin
JP2930713B2 (ja) * 1989-08-16 1999-08-03 カイロン コーポレイション タンパク質ホルモン形成の抑制用の組成物およびその使用法
AU644621B2 (en) * 1989-12-18 1993-12-16 Transgene S.A. Pharmaceutical composition for treating or preventing retroviral infections
GR1001044B (el) * 1991-06-03 1993-04-28 Logothetou Rella Eleni Μηχανισμός διή?ησης νεοπλασματικών κυττάρων και η χρήση του αναστολέα της Ca2+ -εξαρτώμενης ουδέτερης πρωτεάσης για την παρασκευή φαρμακευτικών αντικαρκινικών συν?έσεων.

Also Published As

Publication number Publication date
DK0666755T3 (da) 2003-08-04
JP2004002455A (ja) 2004-01-08
RO116164B1 (ro) 2000-11-30
PL307864A1 (en) 1995-06-26
HU218892B (hu) 2000-12-28
CZ55995A3 (en) 1996-01-17
WO1994006454A3 (fr) 1994-08-18
FI951078A (fi) 1995-03-08
DE69332904D1 (de) 2003-05-28
WO1994006454A2 (fr) 1994-03-31
EP0666755B1 (fr) 2003-04-23
RU2126266C1 (ru) 1999-02-20
KR950703357A (ko) 1995-09-20
NO950897D0 (no) 1995-03-08
NZ256246A (en) 1997-08-22
JP3517238B2 (ja) 2004-04-12
HU9500682D0 (en) 1995-04-28
OA10133A (en) 1996-12-18
CA2141951A1 (fr) 1994-03-31
SK29795A3 (en) 1997-02-05
ATE238062T1 (de) 2003-05-15
DE69332904T2 (de) 2003-11-06
NO315546B1 (no) 2003-09-22
FI951078A0 (fi) 1995-03-08
UA41338C2 (uk) 2001-09-17
SK281127B6 (sk) 2000-12-11
AU681350B2 (en) 1997-08-28
EP0666755A1 (fr) 1995-08-16
KR100273620B1 (ko) 2000-12-15
RU95109909A (ru) 1997-03-27
JPH08505042A (ja) 1996-06-04
CA2141951C (fr) 2007-04-24
AU4853093A (en) 1994-04-12
ES2197153T3 (es) 2004-01-01
NO950897L (no) 1995-03-08
PT666755E (pt) 2003-09-30
CZ286953B6 (en) 2000-08-16
HUT75126A (en) 1997-04-28

Similar Documents

Publication Publication Date Title
MX9706913A (es) Compuestos de bis-aminacido-hidroxietilamina-sulfonamida inhibidoresde proteasan retroviral, composiciones que los contienen y ek uso de los mismos.
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
MX9706947A (es) Inhibidores de proteasa retroviral de sulfonilalcanoilamino-hidroxietilamino-sulfonamida y uso de los mismos.
PL322784A1 (en) Amino acid hydroxyethylaminosulphonamides as inhibitors of retroviral protease
AU5417896A (en) Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
AP9200410A0 (en) Retroviral protease inhibitors.
AU8125694A (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
MD960172A (en) 5,6-dihydropyrone derivatives as proteaze inhibitors and antiviral agents
HUT75126A (en) Inhibition of retrovirus infection
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
MX9706912A (es) Inhibidores de protesa retroviral de sulfonamida de hidroxietilamino de amino acido y uso de los mismos.
GEP19991605B (en) Inhibitor, Its Obtaining and Use
MX9304351A (es) Inhibidores de proteasas de aminodiol y composiciones farmaceuticas que los incluyen.